Cerebral 3-[18F]fluoro-5-(2-pyridinylethynyl)benzonitrile ([18F]FPEB) uptake and fragile X messenger ribonucleoprotein in men with fragile X syndrome

<p>Legends.&nbsp;Cerebral3-[¹⁸F]fluoro-5-(2-pyridinylethynyl)benzonitrile([¹⁸F]FPEB)uptake&nbsp;and&nbsp;fragileX&nbsp;messenger ribonucleoprotein&nbsp;in men&nbsp;with fragile&nbsp;X syndrome</p> <p>Table S1. Concomitant medications of participants&nbsp;from the Institute for Neurodegenerative Disorders (IND)</p> <p>Table S2. Demographic and clinical characteristics of participants from the Institute for Neurodegenerative Disorders (IND)</p> <p>Table S3. Demographic and clinical characteristics&nbsp;of participants from the Johns Hopkins University (JHU)</p> <p>Table S4. Genetic and psychological assessments of participants from the Institute for Neurodegenerative Disorders (IND)</p> <p>Table S5. Genetic and psychological assessments of participants&nbsp;from the Johns Hopkins University (JHU)</p> <p>Table S6. Fragile X Mental Retardation Protein (FMRP) in nanogram per microgram total protein for ten healthy people with typical development (TD) with normal CGG repeat sizes [range (20, 37)] utilizing the same analyses as the other participants</p> <p>Table S7. Positron emission tomography (PET) data and analyses for participants from the Institute for Neurodegenerative Disorders (IND)</p> <p>Table S8. Positron emission tomography (PET) data and analysis of participants from the Johns Hopkins University (JHU)</p> <p>Table S9. Correlation coefficients between&nbsp;Fragile X Mental Retardation Protein (FMRP) (Table S4) and [18F]FPEB uptake (Wong DF et al. 2013) for participants with fragile X syndrome (Table S7)</p> <p>Table S10. Correlation coefficients between Fragile X Mental Retardation Protein (FMRP) (Table S4) and [18F]FPEB uptake (Wong DF et al. 2013) for participants with fragile X syndrome and fragile X syndrome-mosaicism&nbsp; (Table S7)</p> <p>Poster.&nbsp;Cerebral3-[¹⁸F]fluoro-5-(2-pyridinylethynyl)benzonitrile([¹⁸F]FPEB)uptake&nbsp;and&nbsp;fragileX&nbsp;messenger ribonucleoprotein&nbsp;in men&nbsp;with fragile&nbsp;X syndrome</p> <p>Video.&nbsp;Cerebral3-[¹⁸F]fluoro-5-(2-pyridinylethynyl)benzonitrile([¹⁸F]FPEB)uptake&nbsp;and&nbsp;fragileX&nbsp;messenger ribonucleoprotein&nbsp;in men&nbsp;with fragile&nbsp;X syndrome</p> <p>The authors thank Flora Tassone, Ph.D., Department of Biochemistry and Molecular Medicine, School of Medicine, &nbsp;UC Davis Health, Sacramento, California, for providing genetic and protein data about participants.</p>